Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Gene / Target16 Peer-Reviewed Briefings
APOE4, Amyloid-β & Tau Axis
Genetic and proteopathic drivers of Alzheimer's disease and neurodegenerative cascades.
Active Specialties:NeurologyNephrologyPsychiatryCardiologyGastroenterology
Plasma pTau217 is a promising prognostic, risk-stratification, and monitoring biomarker (measurable biological signal) of clinical progression in LBD, underscoring its... Although plasma phosphorylated tau-217 (pTau217) detects co-occurring Alzheimer disease (AD) neuropathologic change in Lewy body disease (LBD), relationships with long-term clinical outcomes remain unclear.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
The long-term predictive ability of blood-based biomarkers for incident dementia in community-dwelling older adults was modest due to poor sensitivity and similar to that of a model containing known risk factors. Blood-based biomarkers are strongly correlated with amyloid positivity in research settings, but their long-term performance in heterogeneous populations remains unclear.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
These findings offer insights into the mechanisms of renal involvement and highlight the complex, context-dependent role of macrophages in amyloid clearance and tissue injury. In renal amyloid light chain amyloidosis, sustained and deep hematologic response drives organ response that continues to improve over time.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Low-dose rapamycin improved brain blood flow in APOE4 carriers, offering a new preventive strategy for Alzheimer's. Declining brain blood flow can precede Alzheimer's symptoms by many years, making it a critical early target for intervention.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Disrupted deep sleep brain waves may be an early, pre-symptomatic indicator of Alzheimer's-related memory loss. This finding offers a potential new biomarker (measurable biological signal) for identifying individuals at risk for Alzheimer's disease much earlier than current clinical methods.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Consequently, almost all prospective cases of Alzheimer's disease might benefit from the development of therapies to modulate APOE's role in the disease's pathophysiology. Moreover, most sporadic early-onset Alzheimer's disease might not occur without the contributions of APOE ε3 and ε4, and the two alleles may be component causes of most forms of Alzheimer's disease arising from highly penetrant genetic mutations and trisomy 21.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
TwV significantly improves personal recovery, showing efficacy (real-world effectiveness in the trial) for individuals with SMHPs who experience distressing voices. Further research comparing TwV with an active control and evaluating its implementation in routine care settings is warranted.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Sustained transthyretin suppression with eplontersen resulted in substantially lower myocardial ECV and favorable changes in cardiac structure, biventricular systolic function, and myocardial deformation compared with placebo (inactive comparison treatment) in a cohort of patients mostly not on background stabilizer at baseline. These findings provide randomized evidence that lowering circulating transthyretin modifies myocardial disease progression in ATTR-CM and support serial multiparametric CMR for characterizing myocardial treatment response.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Among patients with TTR amyloidosis with cardiomyopathy, eplontersen modestly attenuated deterioration in prognostically important measures of LV systolic, diastolic and right ventricular function, primarily among patients not receiving stabilizers at baseline. These findings complement the clinical findings of CARDIO-TTRansform and suggest that TTR silencing may attenuate progression of cardiac dysfunction in TTR amyloidosis with cardiomyopathy.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
PD GBA1 exhibits accelerated domain-generalized and more severe cognitive decline compared to PD GBA1_wildtype . Published in Annals of neurology, these peer-reviewed neurology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Elevated expression of several cytokines in the CSF of virologically suppressed PWH indicates persistent immune activity and supports the existence of a central nervous system (CNS) reservoir. Numerous cytokines showed favorable associations with NP data, including "proinflammatory" cytokines such as IL-6 and TNF-α and several chemotactic cytokines, whereas some "anti-inflammatory" cytokines such as IL-10 correlated positively with unfavorable neurodegenerative markers.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
This study clarifies how vascular and neurodegenerative processes interact to shape cognitive impact and inform mechanistic preventions. Mediation analyses indicated that ADNC statistically accounted for about 13-29% of the associations between arteriolosclerosis and cognition across domains and 64-91% of the associations between CAA and cognition.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
The SAA-FPR2 pathway emerges as a potential mediator of inflammation in AH, offering potential therapeutic targets for this severe disease. This study provides new insights into the cellular heterogeneity and dynamics in ALD progression, dissecting AH at a single-cell level.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Together, these findings suggest that filamin-A-dependent cytoskeletal stress acts as an upstream molecular context in which immediate early gene-centred transcriptional dysregulation emerges and becomes linked to dopaminergic vulnerability in progressive supranuclear palsy. Multi-layered analyses revealed cortical monoamine depletion together with early striatal dopaminergic sensitization, indicating a close association between immediate early gene dysregulation and dopaminergic circuit imbalance.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
1 min read·Brain: A Journal of Neurology·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”
